Last reviewed · How we verify

NCT04926909

Study on Serum Cystatin C and PET-DAT in Patients With Parkinson's Disease

Status unknown Last updated 15 June 2021
What this trial tests

trial in Parkinson's Disease in 121 participants. Status unknown.

Timeline
1 July 2020
Primary endpoint
1 July 2021
1 August 2021

Quick facts

Lead sponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment121
Start date1 July 2020
Primary completion1 July 2021
Estimated completion1 August 2021
Sites1 location across China

Conditions studied

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 20 to 80, any sex, with Parkinson's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the relationship between serum cystatin C and dopamine receptor(DAT) loss in patients with parkinson's disease(PD)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Parkinson's Disease

Currently open trials in the same condition.

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04926909.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing